Get the Stockscreener App
2.22
2.63%
-0.06
After Hours:
2.20
-0.02
-0.90%
Phio Pharmaceuticals Corp stock is traded at $2.22, with a volume of 801.06K.
It is down -2.63% in the last 24 hours and up +16.84% over the past month.
Phio Pharmaceuticals Corp is a clinical-stage biotechnology company whose proprietary INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. The Company is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems.
See More
Previous Close:
$2.28
Open:
$2.14
24h Volume:
801.06K
Relative Volume:
0.14
Market Cap:
$10.60M
Revenue:
-
Net Income/Loss:
$-11.66M
P/E Ratio:
-0.2722
EPS:
-8.156
Net Cash Flow:
$-11.09M
1W Performance:
-5.13%
1M Performance:
+16.84%
6M Performance:
-33.73%
1Y Performance:
-57.96%
1-Day Range:
$2.085
$2.35
1-Week Range:
$1.93
$2.86
52-Week Range:
$1.53
$10.35
Phio Pharmaceuticals Corp Stock (PHIO) Company Profile
Name
Phio Pharmaceuticals Corp
Sector
Industry
Phone
(508) 767-3861
Address
11 APEX DRIVE, SUITE 300A, MARLBOROUGH, MA
Compare PHIO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PHIO
Phio Pharmaceuticals Corp
|
2.22 | 10.60M | 0 | -11.66M | -11.09M | -8.156 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.40 | 112.90B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
683.08 | 75.06B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
665.68 | 40.45B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
277.16 | 35.75B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
120.88 | 28.98B | 3.30B | -501.07M | 1.03B | -2.1146 |
Phio Pharmaceuticals Corp Stock (PHIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-05-20 | Initiated | H.C. Wainwright | Buy |
Phio Pharmaceuticals Corp Stock (PHIO) Latest News
Phio Pharmaceuticals (PHIO) Stock Price, News & Analysis - MarketBeat
Phio Pharmaceuticals CEO to Present Breakthrough Cancer Treatment at Renmark Virtual Roadshow - StockTitan
Phio Pharmaceuticals Announces Closing of $1.83 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules - Newsfile
Phio Pharmaceuticals Secures $1.83M Direct Offering to Advance Cancer Treatment Pipeline - StockTitan
We Asked Retail What's Next For Phio Pharma After Monday's Blistering Rally: Most See More Room To Run - MSN
Phio Pharmaceuticals Raises $1.83M in Direct Offering with Warrant Coverage at $3.00/Share - StockTitan
Stock market news: Phio Pharmaceuticals +50.19%, DatChat +46.01% among top gainers during mid day trading - Business Upturn
Stock market today: Phio Pharmaceuticals -20.76%, Soligenix -20.15% among biggest losers in early trading - Business Upturn
Phio Pharmaceuticals Raises $2.5M Through Direct Offering at $3.00 Per Share - StockTitan
Phio Pharmaceuticals sharply lower on equity offering - MSN
Stock market news: Phio Pharmaceuticals -50.61%, Salarius Pharmaceuticals -28.61% among biggest losers during mid day trading - Business Upturn
Stock market news: Eterna Therapeutics posted gain of 100.87% while Phio Pharmaceuticals saw loss of 50.44% during mid day trading - Business Upturn
What's Going On With Phio Pharmaceuticals Stock Today? - Benzinga
Stock market today: Phio Pharmaceuticals -41.48%, Aehr Test Systems -26.86% among biggest losers in early trading - Business Upturn
Stock market today: Eterna Therapeutics gain over 136.63% while Phio Pharmaceuticals plunged by 40.25% in early trading - Business Upturn
Nasdaq Jumps 150 Points; US Producer Prices Increase 0.2% In December - Benzinga
Phio Pharmaceuticals Announces $3.19 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules - Newsfile
Phio stock surged 330%: Phio reports 100% tumor clearance - Markets.com
Stocks to Watch in 2025: PHIO, LPTH, KAVL, Promising Innovations, Growth Opportunities, Etc. … more inside - newschannelnebraska.com
Phio Pharma Stock Quadruples On Positive Data From Cancer Treatment Trial: Retail’s Elated - MSN
Phio Pharmaceuticals skyrockets on skin cancer drug trial success - Mugglehead
Stocks to Watch in 2025: PHIO, LPTH, KAVL, Promising Innovations, Growth Opportunities, Etc. ... more inside - openPR
Gold Down Over 1%; Salarius Pharmaceuticals Shares Surge - Benzinga
Unlocking the Surge! Phio Pharmaceuticals Surprises Everyone with 300% Stock Surge - Elblog.pl
Cancer-Focused Phio Pharmaceuticals Stock Gains 300% On MondayHere's Why - Benzinga
Stock market news: Phio Pharmaceuticals +296.88%, Salarius Pharmaceuticals +153.67% among top gainers during mid day trading - Business Upturn
Stock market news: Shallgo saw rise of 286.81% while Kairos Pharma was up by 176.47% during mid day trading - Business Upturn
Stocks to Watch in 2025: PHIO, LPTH, KAVL and more - Markets.com
Phio reports complete tumor clearance in two cancer patients By Investing.com - Investing.com South Africa
US Stocks Mixed; Nasdaq Down Over 1% - Benzinga
Stock market today: Phio Pharmaceuticals +289.93%, Sage Therapeutics +34.95% among the top gainers in early trading - Business Upturn
Phio Pharma Shares Triple After Positive Trial Data for Cancer Treatment - MarketWatch
Pre-Market Surge For Phio Pharmaceuticals Following Clinical Success - Stocks Telegraph
PHIOPhio Pharmaceuticals Corp. Latest Stock News & Market Updates - StockTitan
Phio reports complete tumor clearance in two cancer patients - Investing.com
Phio Pharmaceuticals Announces Promising Results of Second Cohort from Its Ongoing Clinical Study of PH-762 - Newsfile
Phio's Cancer Drug PH-762 Achieves Complete Tumor Clearance in Phase 1b Trial Patients - StockTitan
Stock market today: Kairos Pharma saw rise of 130.20% and Salarius Pharmaceuticals was up by 180.52% in early trading - Business Upturn
Phio reports potential hyperpigmentation treatment success - Investing.com
Comfort Systems USA (FIX-N) QuotePress Release - The Globe and Mail
Phio Pharmaceuticals Announces Publication in Clinical, Cosmetic and Investigational Dermatology - Newsfile
Phio's RXI-231 Shows Promise in Groundbreaking Hyperpigmentation Treatment Study - StockTitan
Why ACADIA Pharmaceuticals Inc. (ACAD) Is Skyrocketing - Yahoo Finance
Phio Pharmaceuticals Corp. Announces Positive Safety Monitoring Committee Recommendation to continue to Third Dose Cohort in its Clinical Study of PH-762 - Marketscreener.com
Phio Pharmaceuticals Announces Registered Direct Offering Priced At-the-Market Under Nasdaq Rules - Newsfile
Phio Pharmaceuticals Announces $480K Direct Offering with Warrant Coverage to Boost Working Capital - StockTitan
Phio Pharmaceuticals Rallies Following Key Trial and Funding Updates - Stocks Telegraph
Why Rumble Shares Are Trading Higher By Around 43%; Here Are 20 Stocks Moving Premarket - Benzinga
As FedEx plans to spin off freight, can it cut costs even more? - Yahoo Finance
Phio stock hits 52-week low at $2.13 amid market challenges - Investing.com
Phio Pharmaceuticals Raises $1.15M Through Strategic Direct Offering and Warrant Placement - StockTitan
Phio Pharmaceuticals Corp Stock (PHIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.49%
0.79%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):